A big data point this morning that is a great sign for Trumpomics. Welcome to the Big Money Show. I'm Taylor Riggs along with my co-hosts Lydia who Lou Basses Jackie D'Angelus and with us for the entire hour Forbes media chairman and editor-inchief Steve Forbes.Great to have you. >> Good to be here. Thank you.So the numbers out this morning, GDP blowing past estimates. The US economy growing at 4.3% in the third quarter. That is the strongest pace in 2 years.That is major momentum heading into Q4. And it's ...

MEXICO CITY, Dec. 23, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that today it completed the payment of the cash dividend previously announced through a Notice of Rights filed with the Mexican Stock Exchange (Bolsa Mexicana de Valores). The dividend amounted to $0.200000 Mexican pesos per share on its common stock ...

US stocks tipped higher on Tuesday, with the S&P 500 clinching a fresh record, as Wall Street shrugged off fresh data that showed surprisingly strong growth in the US economy over the summer that led investors to trim bets on near-term interest-rate cuts. The S&P 500 (^GSPC) edged up 0.5% to notch a record close of 6,909.79. The tech-heavy Nasdaq Composite (^IXIC) rose 0.6%. The blue-chip benchmark Dow Jones Industrial Average (^DJI) gained around 0.2%. The major averages extended gains for a fourth strai ...

Wage Garnishments for Defaulted Student Loans - The Department of Education will begin garnishing wages for defaulted federal student loan borrowers starting January 7, with approximately 1,000 borrowers notified initially [2] - Borrowers who default, typically after not making payments for over 270 days, may have up to 15% of their income garnished to cover missed payments [3] - As of September 30, 2025, there are 5.2 million borrowers in default, with nearly 6.6 million more delinquent between one month and one year [4] Economic Growth and Federal Reserve - The U.S. economy grew at an annual rate of 4.3% in the third quarter, surpassing the expected 3.2% growth, driven by a decrease in imports and a 3.5% rise in consumer spending [25][26] - The Federal Reserve is scheduled to meet on January 27 and 28, with expectations to hold interest rates steady after recent cuts aimed at preventing job market slowdown [27][28] - Fed officials face a dilemma between lowering rates to support employment and maintaining higher rates to combat inflation, as both metrics have shown concerning trends [29][30] Novo Nordisk and FDA Approval - Novo Nordisk's stock surged approximately 8% following FDA approval of its Wegovy pill for weight management, expected to launch in early January [31][32] - The approval positions Novo Nordisk favorably against competitors like Eli Lilly, whose weight-loss pill is anticipated for approval in the first quarter of 2026 [33]

Core Viewpoint - Truist Securities has raised its price target on Cytokinetics, Inc. to $84 from $70 while maintaining a Buy rating, reflecting updated forecasts following the regulatory approval of MYQORZO [1] Group 1: Regulatory Approval and Market Potential - The recent approval of MYQORZO, which features a differentiated label, positions it to become a significant revenue driver in obstructive hypertrophic cardiomyopathy (oHCM) [2] - Truist updated its model to estimate worldwide peak sales for MYQORZO in oHCM at $3.7 billion, slightly below the $3.8 billion consensus estimate [2] Group 2: Revenue Projections and Launch Expectations - A steady launch of MYQORZO is expected to begin in early 2026, with performance anticipated to be at least comparable to the launch trajectory of Camzyos [3] - Truist modeled fiscal 2026 aficamten revenue at $106 million, aligning with consensus expectations [3] - Looking ahead, the analyst projects worldwide peak adjusted total revenue of $4.6 billion in 2035, marginally above the $4.5 billion consensus estimate [3]

Core Viewpoint - Jones Trading initiated coverage on MindMed (NASDAQ: MNMD) with a Buy rating and a $61 price target, highlighting the company's position in the expanding field of psychedelic-based neuropsychiatric treatments [1] Group 1: Company Positioning - MindMed is well positioned to benefit from favorable trends in the development of psychedelic agents for mental health [2] - Strong clinical data from earlier-stage trials is expected to lead to positive Phase III outcomes for MindMed's lead asset, MM120, in treating generalized anxiety disorder and major depressive disorder [2] Group 2: Clinical and Regulatory Considerations - There are unique clinical and regulatory risks associated with MM120 due to its relationship with LSD, which is classified as a Schedule I substance in the United States [3] - Compelling Phase III data could support eventual regulatory approval, and LSD's long history may enhance awareness and facilitate rapid commercial uptake if approved [3] Group 3: Market Performance and Opportunities - Despite a strong stock performance in 2025, with shares up approximately 69% year to date, the market is perceived to underestimate the long-term opportunity while overestimating clinical and regulatory hurdles [4]

Key Takeaways BMY will give Eliquis free to Medicaid and donate more than 7 tons of its active ingredient. Eliquis is Bristol Myers Squibb's top drug, posting $11B in sales in the first nine months of 2025. The government deal grants BMY three years of tariff relief and no future pricing mandates.Bristol Myers Squibb (BMY) announced a pricing agreement with the U.S. government to supply Eliquis (apixaban) at no cost to Medicaid beginning Jan. 1, 2026. BMY will also donate more than 7 tons of the active phar ...

The pill is 25 milligrams of semaglutide, the same active ingredient in injectable Wegovy and Ozempic, and will be sold under the brand name Wegovy. Novo already sells an oral semaglutide for type 2 diabetes, Rybelsus. The U.S. Food and Drug Administration approved Novo Nordisk's weight-loss pill on Monday, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly. The approval could help spur a turnaround f ...

Core Insights - BioMarin Pharmaceutical Inc. has acquired Amicus Therapeutics for $4.8 billion to enhance its market position in the rare genetic diseases sector against competitors like Alexion Pharmaceuticals and Vertex Pharmaceuticals [1][4] Acquisition Details - The acquisition involves purchasing all outstanding shares of Amicus at $14.50 per share, representing a 33% premium over its previous closing price [5] - The deal is financed through BioMarin's cash reserves and $3.7 billion in non-convertible debt, strategically avoiding equity dilution [2][6] - The acquisition is expected to close in the second quarter of 2026 and will add Amicus' therapies, Galafold and Pombiliti-Opfolda, which generated $449 million in sales in the first nine months of 2025, to BioMarin's portfolio [5][6] Market Reaction - Following the acquisition announcement, BioMarin's stock surged by 18%, while Amicus' stock increased by 30%, indicating strong investor confidence in the strategic benefits of the acquisition [2][7] - Joon Lee from Truist Financial set a price target of $100 for BioMarin, suggesting a potential upside of 68.7% from its trading price of $59.28 at the time of the announcement [4]

The approval of Novo Nordisk's (NYSE:NVO) oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to choose one specific company.• What should traders watch with XLV?Broad funds like the Health Care Select Sector SPDR Fund (NYSE:XLV) and the Vanguard Health Care ETF (NYSE:VHT) offer diversified exposure to major drugmakers, such as Novo Nordisk and Eli Lilly And Co (NYSE:LLY) , as well as insurers and health care ...